A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

Pathogens and Global Health

Volumn 107, Issue 5, 2013, Pages 242-252

  Babokhov, Peter ^a   Sanyaolu, Adekunle O ^b   Oyibo, Wellington A ^c   Fagbenro Beyioku, Adetayo F ^c   Iriemenam, Nnaemeka C ^c  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

^c UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Chemotherapy; Control; Human African trypanosomiasis; Resistance; Sub Saharan Africa

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2, 5 BIS (4 AMIDINOPHENYL) FURAN; ANTITRYPANOSOMAL AGENT; APREPITANT; AZATHIOPRINE; CORDYCEPIN; CPD 0802; CYCLODEXTRIN; DB 868; DIAMINOTRIAZINE; DIMERCAPROL; EFLORNITHINE; FEXINIDAZOLE; MELARSENOXIDE; MELARSOPROL; MULTIDRUG RESISTANCE PROTEIN; NIFURTIMOX; OXABOROLE; PAFURAMIDINE; PENTAMIDINE; PENTOSTATIN; PREDNISOLONE; SCYX 7158; SUBSTANCE P DERIVATIVE; SURAMIN; TRYBIZINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AFRICAN TRYPANOSOMIASIS; ANAPHYLACTIC SHOCK; ANEMIA; ARTHRALGIA; CHEMOTHERAPY; DIARRHEA; DIZZINESS; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; PANCREAS DISEASE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEIZURE; THROMBOCYTOPENIA; TRYPANOSOMA BRUCEI; TRYPANOSOMA RHODESIENSE;

EID: 84881164937     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773213Y.0000000105     Document Type: Review

References (57)

1. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases. Lancet. 2003;362:1469-80.
2. WHO. WHO/NTD Report update 2011. http://wwwwhoint/ neglected_diseases/2010report/WHO_NTD_report_update_20 11pdf, 1-25. 2011.
3. WHO. Neglected Tropical Diseases Booklet 2010. Neglected tropical diseases, hidden successes, emerging opportunities. 2010. http://whqlibdoc.who.int/publications/2009/9789241598705_eng. pdf, 1-71.
4. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010;9:57.
5. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis. 2011;5:e1007.
6. WHO. African trypanosomiasis (sleeping sickness). 2012. http:// wwwwhoint/mediacentre/factsheets/fs259/en/ (accessed 2012 April 4).
7. Simarro PP, Franco JR, Cecchi G, Paone M, Diarra A, Ruiz Postigo JA, et al. Human African trypanosomiasis in nonendemic countries (2000-2010). J Travel Med. 2012;19:44-53.
8. Pepin J, Khonde N. Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Trans R Soc Trop Med Hyg. 1996;90:183-6.
9. Tong J, Valverde O, Mahoudeau C, Yun O, Chappuis F. Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl Health. 2011;5:7.
10. Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, McKerrow J, et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest. 2008;118:1301-10.
11. Baral TN. Immunobiology of African trypanosomes: need of alternative interventions. J Biomed Biotechnol. 2010;2010: 389153.
12. Stockdale C, Swiderski MR, Barry JD, McCulloch R. Antigenic variation in Trypanosoma brucei: joining the DOTs. PLoS Biol. 2008;6:e185.
13. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148-59.
14. Matovu E, Seebeck T, Enyaru JC, Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001;3:763-70.
15. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2007;152:1155-71.
16. Worthen C, Jensen BC, Parsons M. Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage Trypanosoma brucei. PLoS Negl Trop Dis. 2010;4:e678.
17. Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors. 2010;3:15.
18. De Koning HP. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol. 2001;59: 586-92.
19. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother. 2009;53:4185-92.
20. Sanderson L, Dogruel M, Rodgers J, De Koning HP, Thomas SA. Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther. 2009;329:967-77.
21. Sanderson L, Khan A, Thomas S. Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob Agents Chemother. 2007;51:3136-46.
22. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg. 2009;103:280-90.
23. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis. 2005;191:1922-31.
24. Kuepfer I, Schmid C, Allan M, Edielu A, Haary EP, Kakembo A, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012;6:e1695.
25. Rodgers J, Bradley B, Kennedy PG. Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitol Int. 2007;56:321-4.
26. Bouteille B, Oukem O, Bisser S, Dumas M. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol. 2003;17:171-81.
27. Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest. 2004;113:496-504.
28. Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104:175-96.
29. Kennedy PG. The pathogenesis and modulation of the posttreatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis. J Neuroimmunol. 1999;100:36-41.
30. Hunter CA, Jennings FW, Kennedy PG, Murray M. The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasis. Neuropathol Appl Neurobiol. 1992;18:619-25.
31. Baker N, de Koning HP, Maser P, Horn D. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 2013;29:110-8.
32. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008;336:705-8.
33. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology. 2012;139:842-6.
34. Sanderson L, Dogruel M, Rodgers J, Bradley B, Thomas SA. The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem. 2008;107:1136-46.
35. Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55:5602-8.
36. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286:13088-95.
37. Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Miaka Mia Bilenge C, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2007;195:322-9.
38. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006;1:e39.
39. Chappuis F. Melarsoprol-free drug combinations for secondstage Gambian sleeping sickness: the way to go. Clin Infect Dis. 2007;45:1443-5.
40. Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst Rev. 2010;8:CD006201.
41. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007;1:e64.
42. Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007;45:1435-42.
43. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4:e720.
44. Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, et al. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4:e923.
45. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E. Drug resistance in human African trypanosomiasis. Future Microbiol. 2011;6:1037-47.
46. Trunz BB, Jedrysiak R, Tweats D, Brun R, Kaiser M, Suwinski J, et al. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur J Med Chem. 2011;46:1524-35.
47. Nesslany F, Brugier S, Mouries MA, Le Curieux F, Marzin D. In vitro and in vivo chromosomal aberrations induced by megazol. Mutat Res. 2004;560:147-58.
48. Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem. 2011;3:1259-78.
49. DNDi. A needs-driven collaborative R&D model for neglected diseases. Geneva, Switzerland: R&D portfolio (Drugs for Neglected Diseases Initiative); 2011.
50. DNDi. DNDi launches phase I in-human clinical trial for promising oral drug for sleeping sickness. Press Releases, 2012. http:// wwwdndiorg/press-releases/press-releases-2012html (accessed 2012 March 29).
51. Barrett MP. Potential new drugs for human African trypanosomiasis: some progress at last. Curr Opin Infect Dis. 2010;23:603-8.
52. Steverding D, Wang X. Evaluation of anti-sleeping-sickness drugs and topoisomerase inhibitors in combination on Trypanosoma brucei. J Antimicrob Chemother. 2009;63:1293-5.
53. Diaz-Gonzalez R, Perez-Pertejo Y, Prada CF, Fernandez-Rubio C, Balana-Fouce R, Reguera RM. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors. Mini Rev Med Chem. 2009;9:674-86.
54. Bakshi RP, Sang D, Morrell A, Cushman M, Shapiro TA. Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother. 2009;53:123-8.
55. Deterding A, Dungey FA, Thompson KA, Steverding D. Antitrypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. 2005;93:311-6.
56. Rodgers J, Jones A, Gibaud S, Bradley B, McCabe C, Barrett MP, et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5:e1308.
57. Vodnala SK, Ferella M, Lunden-Miguel H, Betha E, van Reet N, Amin DN, et al. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009;3:e495.